PARIS (Reuters) - Sanofi said its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval. Eliglustat tartrate could become the first oral treatment for Gaucher disease - a rare genetic disorder affecting some 10,000 patients - and shake up the market for therapies that currently have to be injected bi-weekly. Eliglustat could generate annual sales of $360 million by 2017, according to ThomsonReuters Pharma forecasts. ...
Continue reading...
No comments:
Post a Comment